BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16087247)

  • 1. Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.
    Thangarajh M; Masterman T; Rot U; Duvefelt K; Brynedal B; Karrenbauer VD; Hillert J
    J Neuroimmunol; 2005 Oct; 167(1-2):210-4. PubMed ID: 16087247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis.
    Thangarajh M; Gomes A; Masterman T; Hillert J; Hjelmström P
    J Neuroimmunol; 2004 Jul; 152(1-2):183-90. PubMed ID: 15223251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production.
    Braun N; Michel U; Ernst BP; Metzner R; Bitsch A; Weber F; Rieckmann P
    Neurosci Lett; 1996 Sep; 215(2):75-8. PubMed ID: 8887999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis.
    Thangarajh M; Masterman T; Hillert J; Moerk S; Jonsson R
    Scand J Immunol; 2007 Jan; 65(1):92-8. PubMed ID: 17212772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency.
    Jin R; Kaneko H; Suzuki H; Arai T; Teramoto T; Fukao T; Kondo N
    Int J Mol Med; 2008 Feb; 21(2):233-8. PubMed ID: 18204790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus.
    Hopia L; Thangarajh M; Khademi M; Laveskog A; Wallström E; Svenungsson E; Andersson M
    Scand J Rheumatol; 2011; 40(5):363-72. PubMed ID: 21585290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel function of TNF cytokines in regulating bone marrow B cell survival.
    Zhang M; Ko KH; Lam QL; Lo CK; Xu DJ; Shen L; Zheng B; Srivastava G; Lu L
    Cell Mol Immunol; 2004 Dec; 1(6):447-53. PubMed ID: 16293214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
    Dong-Si T; Weber J; Liu YB; Buhmann C; Bauer H; Bendl C; Schnitzler P; Grond-Ginsbach C; Grau AJ
    J Neurol; 2004 May; 251(5):542-7. PubMed ID: 15164186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Deficient mRNA expression of specific protein 3 gene in peripheral blood mononuclear cells from patients with multiple sclerosis].
    Lin AY; Yang QD; Murong SX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):187-9. PubMed ID: 18393243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis.
    Desplat-Jégo S; Feuillet L; Creidy R; Malikova I; Rance R; Khrestchatisky M; Hahm K; Burkly LC; Pelletier J; Boucraut J
    J Leukoc Biol; 2009 Jan; 85(1):132-5. PubMed ID: 18945822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis.
    Kantarci OH; Morales Y; Ziemer PA; Hebrink DD; Mahad DJ; Atkinson EJ; Achenbach SJ; De Andrade M; Mack M; Ransohoff RM; Lassmann H; Bruck W; Weinshenker BG; Lucchinetti CF
    J Neuroimmunol; 2005 Dec; 169(1-2):137-43. PubMed ID: 16182378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis.
    Liu GZ; Gomes AC; Putheti P; Karrenbauer V; Kostulas K; Press R; Hillert J; Hjelmström P; Gao XG
    Scand J Immunol; 2006 Oct; 64(4):412-9. PubMed ID: 16970683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
    Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
    Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.
    Sellebjerg F; Börnsen L; Khademi M; Krakauer M; Olsson T; Frederiksen JL; Sørensen PS
    Neurology; 2009 Dec; 73(23):2003-10. PubMed ID: 19996075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features.
    Bojarska-Junak A; Hus I; Chocholska S; Wasik-Szczepanek E; Sieklucka M; Dmoszyńska A; Roliński J
    Leuk Res; 2009 Oct; 33(10):1319-27. PubMed ID: 19395025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
    Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
    Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis.
    Thangarajh M; Kisiswa L; Pirskanen R; Hillert J
    Scand J Immunol; 2007 May; 65(5):461-6. PubMed ID: 17444957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.